- Home
- TSHA vs IGR Comparison
TSHA vs IGR Comparison
Compare TSHA & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- IGR
- Stock Information
- Founded
- TSHA 2019
- IGR 2004
- Country
- TSHA United States
- IGR United States
- Employees
- TSHA N/A
- IGR N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- IGR Finance Companies
- Sector
- TSHA Health Care
- IGR Finance
- Exchange
- TSHA Nasdaq
- IGR Nasdaq
- Market Cap
- TSHA 728.4M
- IGR 752.8M
- IPO Year
- TSHA 2020
- IGR N/A
- Fundamental
- Price
- TSHA $2.94
- IGR $4.92
- Analyst Decision
- TSHA Strong Buy
- IGR
- Analyst Count
- TSHA 7
- IGR 0
- Target Price
- TSHA $8.71
- IGR N/A
- AVG Volume (30 Days)
- TSHA 2.7M
- IGR 747.7K
- Earning Date
- TSHA 08-12-2025
- IGR 01-01-0001
- Dividend Yield
- TSHA N/A
- IGR 13.93%
- EPS Growth
- TSHA N/A
- IGR N/A
- EPS
- TSHA N/A
- IGR N/A
- Revenue
- TSHA $8,098,000.00
- IGR N/A
- Revenue This Year
- TSHA N/A
- IGR N/A
- Revenue Next Year
- TSHA N/A
- IGR N/A
- P/E Ratio
- TSHA N/A
- IGR N/A
- Revenue Growth
- TSHA N/A
- IGR N/A
- 52 Week Low
- TSHA $1.05
- IGR $3.88
- 52 Week High
- TSHA $3.31
- IGR $5.70
- Technical
- Relative Strength Index (RSI)
- TSHA 62.34
- IGR 43.69
- Support Level
- TSHA $2.69
- IGR $4.80
- Resistance Level
- TSHA $3.12
- IGR $4.94
- Average True Range (ATR)
- TSHA 0.17
- IGR 0.07
- MACD
- TSHA 0.02
- IGR 0.01
- Stochastic Oscillator
- TSHA 68.97
- IGR 72.50
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.